Guideline-based statin eligibility, coronary artery calcification, and cardiovascular events

JAMA

Volumn 314, Issue 2, 2015, Pages 134-141

  Pursnani, Amit ^a,b   Massaro, Joseph M ^c,d   D'Agostino, Ralph B ^d,e   O'Donnell, Christopher J ^a,d,f   Hoffmann, Udo ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d FRAMINGHAM HEART STUDY   (United States)

^e Boston University   (United States)

^f NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; CHOLESTEROL;

ADULT; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY CALCIUM SCORE; FEMALE; FRAMINGHAM RISK SCORE; HEALTH PROGRAM; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; INCIDENCE; INTERMEDIATE RISK POPULATION; ISCHEMIC HEART DISEASE; LONGITUDINAL STUDY; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MULTIDETECTOR COMPUTED TOMOGRAPHY; PATIENT IDENTIFICATION; PRACTICE GUIDELINE; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; AGED; BLOOD; CALCINOSIS; CARDIOVASCULAR DISEASES; COMPARATIVE STUDY; COMPLICATION; CORONARY ARTERY DISEASE; HYPERCHOLESTEROLEMIA; KAPLAN MEIER METHOD;

AGED; CALCINOSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL; CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 84937460144     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.7515     Document Type: Article

References (23)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19): 2486-2497.
2. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421.
3. Grundy SM, Cleeman JI, Merz CN, et al; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J AmColl Cardiol. 2004;44(3):720-732.
4. Stone NJ, Robinson J, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J AmColl Cardiol. 2014;63(25 pt B):2889-2934.
5. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J AmColl Cardiol. 2014;63(25 pt B):2935-2959.
6. Guallar E, Laine C. Controversy over clinical guidelines: listen to the evidence, not the noise. Ann Intern Med. 2014;160(5):361-362.
7. Martin SS, Blumenthal RS. Concepts and controversies: the 2013 American College of Cardiology/American Heart Association risk assessment and cholesterol treatment guidelines. Ann Intern Med. 2014;160(5):356-358.
8. Pencina MJ, Navar-Boggan AM, D'Agostino RB Sr, et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med. 2014; 370(15):1422-1431.
9. Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in 4 racial or ethnic groups. N Engl J Med. 2008;358(13):1336-1345.
10. Hoffmann U, Massaro JM, Fox CS, Manders E, O'Donnell CJ. Defining normal distributions of coronary artery calcium in women and men (from the Framingham Heart Study). Am J Cardiol. 2008; 102(9):1136-1141.
11. Lehman SJ, Massaro JM, Schlett CL, O'Donnell CJ, Hoffmann U, Fox CS. Peri-aortic fat, cardiovascular disease risk factors, and aortic calcification: the Framingham Heart Study. Atherosclerosis. 2010;210(2):656-661.
12. Preis SR, Hwang SJ, Fox CS, et al. Eligibility of individuals with subclinical coronary artery calcium and intermediate coronary heart disease risk for reclassification (from the Framingham Heart Study). Am J Cardiol. 2009;103(12):1710-1715.
13. Thanassoulis G, Massaro JM, Cury R, et al. Associations of long-term and early adult atherosclerosis risk factors with aortic and mitral valve calcium. J AmColl Cardiol. 2010;55(22):2491-2498.
14. Hong C, Bae KT, PilgramTK. Coronary artery calcium: accuracy and reproducibility of measurements with multi-detector row CT-assessment of effects of different thresholds and quantificationmethods. Radiology. 2003;227 (3):795-801.
15. Hoffmann U, Siebert U, Bull-Stewart A, et al. Evidence for lower variability of coronary artery calcium mineral mass measurements by multi-detector computed tomography in a community-based cohort-consequences for progression studies. Eur J Radiol. 2006;57(3):396-402.
16. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-753.
17. Paixao AR, Ayers CR, Berry JD, de Lemos JA, Khera A. Atherosclerotic cardiovascular disease prevention: a comparison between the third Adult Treatment Panel and the new 2013 treatment of blood cholesterol guidelines. Circ Cardiovasc Qual Outcomes. 2014;7(5):778-779.
18. AllisonMA,Wright M, Tiefenbrun J. The predictive power of low-density lipoprotein cholesterol for coronary calcification. Int J Cardiol. 2003;90(2-3):281-289.
19. Paramsothy P, Katz R, Owens DS, Burke GL, Probstfield JL, O'Brien KD. Age-modification of lipoprotein, lipid, and lipoprotein ratio-associated risk for coronary artery calcium (from the Multi-Ethnic Study of Atherosclerosis [MESA]). Am J Cardiol. 2010;105(3):352-358.
20. Wong ND, Kawakubo M, LaBree L, Azen SP, XiangM, Detrano R. Relation of coronary calcium progression and control of lipids according to National Cholesterol Education Program guidelines. Am J Cardiol. 2004;94(4):431-436.
21. Johnson KM, Dowe DA. Accuracy of statin assignment using the 2013 AHA/ACC cholesterol guideline vs the 2001 NCEP ATP III guideline: correlation with atherosclerotic plaque imaging. J AmColl Cardiol. 2014;64(9):910-919.
22. Polonsky TS,McClelland RL, Jorgensen NW, et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA. 2010;303(16):1610-1616.
23. Safford MM, Brown TM, Muntner PM, et al; REGARDS Investigators. Association of race and sex with risk of incident acute coronary heart disease events. JAMA. 2012;308(17):1768-1774.